{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/","result":{"pageContext":{"chapter":{"id":"fffdcf61-8f20-593c-9fbc-a4de125dab35","slug":"childhood-immunization-programme-coverage","fullItemName":"Childhood immunization programme coverage","depth":2,"htmlHeader":"<!-- begin field 8f1ecf78-6a4f-491d-94f5-3dfe2bee160b --><h2>What diseases does the childhood immunization programme cover?</h2><!-- end field 8f1ecf78-6a4f-491d-94f5-3dfe2bee160b -->","summary":"","htmlStringContent":"<!-- begin item 1a789e94-e001-4f26-ac5a-24410e86f100 --><!-- begin field ff5d4a87-5965-4adf-9d7d-3e3e617a6a66 --><ul><li>This section gives a brief description of the diseases prevented by the Childhood Immunization Programme and how common they are. For information on the clinical features of these diseases, their historical prevalence, and the impact vaccination has had on them, see the sections on:<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#diphtheria\">Diphtheria</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#haemophilus-influenzae\">Haemophilus influenzae</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#hepatitis-b\">Hepatitis B</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#human-papillomavirus\">Human papillomavirus</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#measles\">Measles</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#meningococcal-infection\">Meningococcal infection</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#mumps\">Mumps</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#pertussis\">Pertussis</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#pneumococcal-disease\">Pneumococcal disease</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#poliomyelitis\">Poliomyelitis</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#rotavirus\">Rotavirus</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#rubella\">Rubella</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-childhood/background-information/childhood-immunization-programme-coverage/#tetanus\">Tetanus</a></li></ul></li></ul><!-- end field ff5d4a87-5965-4adf-9d7d-3e3e617a6a66 --><!-- end item 1a789e94-e001-4f26-ac5a-24410e86f100 -->","topic":{"id":"141a79f8-bf34-5bd6-9d3e-4e2d2e1c98f3","topicId":"884b0998-c242-4b76-869c-7e1d7203ac34","topicName":"Immunizations - childhood","slug":"immunizations-childhood","lastRevised":"Last revised in November 2020","chapters":[{"id":"6ba54a01-de23-5846-8b4d-e24477c75832","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8ca5ebce-3bb6-51f5-897f-9f02d913dd37","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"49b0da44-2af1-559a-aa3d-b7492cc9ee0d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69eb6e91-b113-53eb-bd4e-6a2f49ca6593","slug":"changes","fullItemName":"Changes"},{"id":"0b393c87-257a-567c-b12f-c3d1f55b13aa","slug":"update","fullItemName":"Update"}]},{"id":"ea1bc6cb-f5cf-5581-8659-301af7d9fb67","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f586895e-7f2d-51ef-baa8-6a9a1e98695f","slug":"goals","fullItemName":"Goals"},{"id":"1420f7f8-09c4-58fa-8d52-9b4a3d2a8ddf","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"16ddc68d-be0a-56cd-b38a-9acdf13a0bfe","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"713a5cac-cd5d-58d0-8793-b453d244027d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a6ab4abc-1ddb-5864-9f72-3eb58c16089a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b3ef6d84-ce51-57df-ba8a-40fbd3b7ceee","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e9c4eca9-e338-5ae7-9ad6-cffd74ef6c52","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9a89a8f0-b573-5292-93a2-1ee7ba24d67e","slug":"the-routine-childhood-immunization-schedule","fullItemName":"The routine childhood immunization schedule"},{"id":"fffdcf61-8f20-593c-9fbc-a4de125dab35","slug":"childhood-immunization-programme-coverage","fullItemName":"Childhood immunization programme coverage"}]},{"id":"e9b881e0-0306-56fc-975a-71fc5731b73a","fullItemName":"Management","slug":"management","subChapters":[{"id":"75d2baa6-d689-537b-985d-3b2b1c30e8b3","slug":"children-up-to-1-year-of-age","fullItemName":"Scenario: Children up to 1 year of age"},{"id":"cb326e70-51cb-5b55-86a4-5d1f28fbcf08","slug":"children-1-2-years-of-age","fullItemName":"Scenario: Children 1-2 years of age"},{"id":"6b4cbafe-fdfb-583a-a3fe-7a96b10253c4","slug":"children-2-10-years-of-age","fullItemName":"Scenario: Children 2-10 years of age"},{"id":"88a19f4f-827e-5331-836f-99c46181a1f9","slug":"children-over-10-years-of-age","fullItemName":"Scenario: Children over 10 years of age"},{"id":"df573b46-28ae-516a-adde-90b8bc742b29","slug":"additional-immunizations","fullItemName":"Scenario: Additional immunizations"}]},{"id":"3a2ea091-53a4-51b4-8c1b-16bbc187300b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"39c5bd91-68df-5d37-bdf6-a3fbf4194d8b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e5eea053-f5bc-5745-955b-0200236a454a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"8546e676-a44d-5c1d-a1b9-5d571b466524","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6b8c8a42-fd07-546b-8ec8-59db2829b422","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"913a73f4-d332-5491-a242-fb9e5fed1e37","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8e7e3dc1-7bda-57e5-ba9b-f03e0049b730","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d5fbf31a-ca3a-5b16-86c7-90949cade220","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e9c4eca9-e338-5ae7-9ad6-cffd74ef6c52","slug":"background-information","fullItemName":"Background information"},"subChapters":[{"id":"a4300690-3f89-5242-a8fb-2ba3eff4d610","slug":"diphtheria","fullItemName":"Diphtheria","depth":3,"htmlHeader":"<!-- begin field 1ae701f4-870b-46d0-a2d8-2be1dc37ac13 --><h3>Diphtheria</h3><!-- end field 1ae701f4-870b-46d0-a2d8-2be1dc37ac13 -->","summary":null,"htmlStringContent":"<!-- begin item 163e5c30-6aed-40a5-82ee-9ab68113df14 --><!-- begin field 02c34d3d-95ea-4138-a4b8-6dbcc89d9797 --><ul><li><strong>Diphtheria is an acute infectious disease caused by toxigenic strains of <em>Corynebacterium diphtheriae</em> and <em>C. ulcerans</em>.</strong> It is characterized by the formation of a grey, thick, fibrinous, adherent membrane (pseudomembrane) affecting the upper respiratory tract.<ul><li>Classical respiratory diphtheria presents with membranous pharyngitis, fever, cervical lymphadenopathy, and oedema of the soft tissues ('bull neck' appearance). In some cases, the pseudomembrane can cause death due to respiratory obstruction.</li><li>Milder infections without toxin production present similarly to streptococcal pharyngitis and may not involve the classical pseudomembrane.</li><li>Cutaneous diphtheria appears as vesicles which become ulcerated and covered with an eschar (hard, bluish-grey, raised membrane), usually on the limbs.</li><li>Diphtheria toxin can also cause heart failure and paralysis by affecting the myocardium, nervous, and adrenal tissues. </li></ul></li><li><strong>The best evidence to support the efficacy of diphtheria-containing vaccines is that the disease has been virtually eradicated in the UK since the immunization programme began in the 1940s.</strong> <ul><li>There were no notifications for toxigenic <em>C. diphtheriae</em> or <em>C. ulcerans</em> in England and Wales in 2014, and no deaths [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2014a</a>]. This compares with 61,000 cases of diphtheria in the UK in 1940, with 3283 deaths [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013a</a>].</li><li>However, it is still prevalent in some countries, emphasizing the need for continued vaccination in the UK to prevent outbreaks from carriers from overseas.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2015a</a>]</p><!-- end field 02c34d3d-95ea-4138-a4b8-6dbcc89d9797 --><!-- end item 163e5c30-6aed-40a5-82ee-9ab68113df14 -->","subChapters":[]},{"id":"d9ef4369-9426-59a3-bcc1-b26aaa0eefe5","slug":"haemophilus-influenzae","fullItemName":"Haemophilus influenzae","depth":3,"htmlHeader":"<!-- begin field ce2ff94c-9013-45ca-834a-32ea2419a29d --><h3>Haemophilus influenzae</h3><!-- end field ce2ff94c-9013-45ca-834a-32ea2419a29d -->","summary":null,"htmlStringContent":"<!-- begin item 7a3ed87b-13d6-4eaf-8363-bd19891ed074 --><!-- begin field 6e3c623e-6ac0-424d-a647-64711bb5beac --><ul><li><strong><em>Haemophilus influenzae</em> (usually the encapsulated strains) can cause serious invasive disease,</strong> especially in young children. There are six typeable capsular serotypes (a–f), with type b causing most clinical disease until the introduction of the vaccine against it.<ul><li>The most common presentations of invasive disease are meningitis (60%), epiglottitis (15%), and bacteraemia without an obvious focus (10%). The remaining 15% of cases are made up of septic arthritis, osteomyelitis, cellulitis, pneumonia, and pericarditis.</li><li>Non-encapsulated strains are most commonly associated with otitis media and respiratory infections (for example exacerbations of chronic bronchitis).</li></ul></li><li><strong>Before vaccination against </strong><strong><em>Haemophilus influenzae</em> type B</strong> (Hib), one in 600 children developed some form of invasive Hib disease before their fifth birthday. <ul><li>Following the introduction of the conjugate Hib vaccine in 1992, the annual incidence of invasive disease caused by the bacteria fell rapidly; from 20.5 in 100,000 children under 5 years of age in 1991, to 0.65 in 100,000 children under 5 years of age in 1998.</li><li>After 1999 there was a small increase in the number of Hib infections reported, but following a booster campaign in 2003, numbers are again declining [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2015b</a>]. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013b</a>]</p><!-- end field 6e3c623e-6ac0-424d-a647-64711bb5beac --><!-- end item 7a3ed87b-13d6-4eaf-8363-bd19891ed074 -->","subChapters":[]},{"id":"9a94a8fd-936c-5864-b6bf-dc246fe38476","slug":"hepatitis-b","fullItemName":"Hepatitis B","depth":3,"htmlHeader":"<!-- begin field 8f733361-a904-4b19-8678-a7b300cd387f --><h3>Hepatitis B</h3><!-- end field 8f733361-a904-4b19-8678-a7b300cd387f -->","summary":null,"htmlStringContent":"<!-- begin item ae361f4d-3684-4afc-a4ae-a7b300cd329a --><!-- begin field 29c8e517-e490-42c2-8171-a7b300cd387f --><ul><li><strong>Hepatitis B is an infection of the liver caused by the hepatitis B virus (HBV).</strong> Most new infections with HBV are sub-clinical or may only cause a flu-like illness. However, acute infection occasionally leads to sudden and severe liver damage which can be fatal. Chronic HBV infection can result in progressive liver disease, leading to cirrhosis (development of scar tissue) in some patients and an increased risk of developing liver cancer.</li><li><strong>In 1992, the World Health Assembly recommended that every country should have a universal hepatitis B immunisation programme by 1997.</strong> Recently, infant combination hepatitis B vaccines (which also protect against diphtheria, tetanus, polio, pertussis and Hib) have become available in the UK. In 2014, the Joint Committee on Vaccination and Immunisation (JCVI) re-evaluated the benefits and cost-effectiveness of a universal hepatitis B infant immunisation programme in the UK and subsequently recommended the use of the hexavalent DTaP/IPV/Hib/HepB combination vaccine for all infants.</li><li><strong>By providing hepatitis B vaccine as part of the combined infant vaccine,</strong> in addition to being protected against diphtheria, tetanus, pertussis, polio and Hib, infants will now have the benefit of protection against hepatitis B virus [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2017</a>].</li></ul><!-- end field 29c8e517-e490-42c2-8171-a7b300cd387f --><!-- end item ae361f4d-3684-4afc-a4ae-a7b300cd329a -->","subChapters":[]},{"id":"8c412e3e-007a-5248-adf1-6be3bf18685c","slug":"human-papillomavirus","fullItemName":"Human papillomavirus","depth":3,"htmlHeader":"<!-- begin field 9dd159b0-f367-4180-8e67-64d8c58105e4 --><h3>Human papillomavirus</h3><!-- end field 9dd159b0-f367-4180-8e67-64d8c58105e4 -->","summary":null,"htmlStringContent":"<!-- begin item de00d604-bbed-4797-95f4-01286f1f3878 --><!-- begin field bf1d7db5-37eb-4b28-8859-bb010ddbf4a5 --><ul><li><strong>Human papillomavirus (HPV) is a double-stranded DNA virus,</strong> with at least 100 types having been documented in humans (around 40 of these infect the genital tract). Genital HPV infections are transmitted through sexual contact with an infected person. </li><li><strong>HPV is the most important cause of cervical cancer,</strong> and the two high-risk HPV types 16 and 18 are responsible for almost 60% and more than 15% of all cervical cancers in Europe, respectively. HPV is also associated with other cancers including of the vulva, vagina, penis, and anus. <ul><li>The time span between infection with HPV and the development of cervical pre-cancerous and cancerous lesions is 1–10 years. </li><li>In 2013, 3,207 new cases of cervical cancer were diagnosed in the UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">Cancer Research UK, 2010</a>].</li><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cervical-cancer-hpv/\">Cervical cancer and HPV</a> and <a class=\"topic-reference external-reference\" href=\"/topics/cervical-screening/\">Cervical screening</a>.</li></ul></li><li>Low-risk HPV types such as 6 and 11 are responsible for genital warts, which are the most commonly diagnosed viral sexually transmitted infection in the UK. Although not life-threatening, genital warts may cause significant morbidity. Warts may appear from 3 weeks to 8 months after primary infection, and treatment may remove the warts but may not eliminate infection, putting the person at risk of recurrence and further viral transmission in the future.</li><li><strong>HPV vaccines are highly effective at preventing the infection of susceptible women</strong> with HPV types covered by the vaccines. Gardasil<sup>®</sup> is the quadrivalent vaccine used in the UK childhood immunization programme and it covers HPV types 6,11,16, and 18.<ul><li>The vaccine is over 99% effective at preventing pre-cancerous lesions associated with HPV types 16 and 18 in young women, and protection is maintained for at least 10 years.</li><li>Gardasil<sup>®</sup> is 99% effective in preventing genital warts associated with HPV types 6 and 11 in young women. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2014b</a>]</p><!-- end field bf1d7db5-37eb-4b28-8859-bb010ddbf4a5 --><!-- end item de00d604-bbed-4797-95f4-01286f1f3878 -->","subChapters":[]},{"id":"c71654e1-d93b-5f63-9315-29e1f11d974b","slug":"measles","fullItemName":"Measles","depth":3,"htmlHeader":"<!-- begin field 087de82c-860a-4961-a46a-ff25e589805d --><h3>Measles</h3><!-- end field 087de82c-860a-4961-a46a-ff25e589805d -->","summary":null,"htmlStringContent":"<!-- begin item 00f341b9-fd05-4536-98bb-f1d07d50de8f --><!-- begin field 273ab16d-7795-4695-9973-05908403508d --><ul><li><strong>Measles (a morbillivirus of the paramyxovirus family) is an acute viral infection</strong><strong>.</strong><ul><li>Clinical features may include malaise; coryza; conjunctivitis; cough; Koplik spots (red spots with a bluish-white centre on the oral mucosa); erythematous, maculopapular rash; and fever.</li><li>Complications include otitis media, pneumonia, diarrhoea, convulsions, or rarely, post-infectious encephalitis (which occurs at around 1 week after the onset of the rash). Sub-acute sclerosing panencephalitis is a rare, fatal, late complication.</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/measles/\">Measles</a>.</li></ul></li><li><strong>Historical evidence shows that the measles vaccine is effective. </strong>As uptake of the vaccine has increased, the incidence of measles has fallen correspondingly. <ul><li>Before the measles vaccine was introduced in 1968, notifications of measles infection in England and Wales varied between 160,000 and 800,000 each year with peaks every 2 years. By the late 1980s, notifications had only reduced to 50,000–100,000 due to low vaccination coverage. When the combined measles, mumps, and rubella (MMR) vaccine was introduced in 1988 and coverage exceeded 90%, notifications fell substantially [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013c</a>]. </li><li>There were 6193 notifications of measles in England and Wales in 2013, with 1843 laboratory-confirmed cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2016a</a>].</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013c</a>]</p><!-- end field 273ab16d-7795-4695-9973-05908403508d --><!-- end item 00f341b9-fd05-4536-98bb-f1d07d50de8f -->","subChapters":[]},{"id":"d2ec05a8-7991-5bc9-a07b-5a240ec92814","slug":"meningococcal-infection","fullItemName":"Meningococcal infection","depth":3,"htmlHeader":"<!-- begin field a6cb04ed-eabe-4e0e-9c18-f95a2c97f9bd --><h3>Meningococcal infection</h3><!-- end field a6cb04ed-eabe-4e0e-9c18-f95a2c97f9bd -->","summary":null,"htmlStringContent":"<!-- begin item e06e6e6d-d5b6-4902-aa6a-42986d2b0ba0 --><!-- begin field 1599d0e4-c913-4bdb-9ff7-3b544b465395 --><ul><li><strong>Meningococcal infection commonly presents as meningitis or septicaemia, or both, and is caused by <em>Neisseria meningitidis</em>. </strong><ul><li>Less commonly, meningococcal infection may present with pneumonia, myocarditis, endocarditis, pericarditis, arthritis, conjunctivitis, urethritis, pharyngitis, or cervicitis.</li><li>Meningococci are distinguished by their antigenic grouping. The most common serogroups in the UK are B, C, W, and Y.</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/meningitis-bacterial-meningitis-meningococcal-disease/\">Meningitis - bacterial meningitis and meningococcal disease</a>.</li></ul></li><li><strong>The best evidence on the effectiveness of the meningococcal group C vaccine (MenC) is an observed fall in the number of cases of meningitis caused by the group C serogroup shortly after the vaccine was introduced in 1999.</strong><ul><li>In England, there were 724 cases of laboratory-confirmed invasive meningococcal disease from July 2014 to June 2015. Of these, 58% were due to meningococcal group B disease (MenB), 24% MenW, 13% MenY, and 4% MenC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2015d</a>].</li><li>In 2015, a four component MenB vaccine was included in the routine UK immunization schedule, and a MenACWY conjugated vaccine was introduced to replace the MenC conjugate vaccine previously given at 14 years of age.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2015e</a>]</p><!-- end field 1599d0e4-c913-4bdb-9ff7-3b544b465395 --><!-- end item e06e6e6d-d5b6-4902-aa6a-42986d2b0ba0 -->","subChapters":[]},{"id":"a75d5e15-1055-5191-9c09-67af548c6487","slug":"mumps","fullItemName":"Mumps","depth":3,"htmlHeader":"<!-- begin field 651acd8f-8b20-43ad-a5c3-45a62875e1be --><h3>Mumps</h3><!-- end field 651acd8f-8b20-43ad-a5c3-45a62875e1be -->","summary":null,"htmlStringContent":"<!-- begin item 75d1c131-26db-4846-9826-d10c709a03f9 --><!-- begin field bf1bfc88-f959-4008-849b-bd26cb95c093 --><ul><li> <strong>Mumps is an acute paramyxovirus infection. </strong><ul><li>It usually presents with unilateral or bilateral parotid swelling, but may be asymptomatic.</li><li>Complications include pancreatitis, oophoritis, orchitis (rarely, it may cause male infertility), aseptic meningitis, and encephalitis.</li><li>Very rarely, mumps may cause permanent unilateral or bilateral sensorineural deafness (estimates vary from 1 in 3400 to 1 in 20,000 infections).</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/mumps/\">Mumps</a>.</li></ul></li><li><strong>Morbidity from mumps has decreased significantly since the introduction of the measles, mumps, and rubella (MMR) vaccine,</strong> a single dose of which confers 61–91% protection against mumps.<ul><li>Before the introduction of the MMR vaccine in 1988, about 1200 hospital admissions annually were due to mumps, and mumps was the most common cause of viral meningitis.</li><li>There was a mumps epidemic in 2005 in England and Wales, mostly in young people aged 15–24 years who had either never received the MMR vaccine as they were too old when it was introduced, or had received only one dose.</li><li>In 2014, there were 2604 laboratory-confirmed cases of mumps in England and Wales [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2016a</a>].</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013e</a>]</p><!-- end field bf1bfc88-f959-4008-849b-bd26cb95c093 --><!-- end item 75d1c131-26db-4846-9826-d10c709a03f9 -->","subChapters":[]},{"id":"b1e15a56-4182-5d90-ada9-fe60c09b15dd","slug":"pertussis","fullItemName":"Pertussis","depth":3,"htmlHeader":"<!-- begin field 36c90406-876c-4e04-8329-80781f1edac6 --><h3>Pertussis</h3><!-- end field 36c90406-876c-4e04-8329-80781f1edac6 -->","summary":null,"htmlStringContent":"<!-- begin item 53e879b1-f6fd-4eb1-9d6e-5938122aefd7 --><!-- begin field 3e69fc4d-8c64-49d3-84bf-27d7178c371d --><ul><li><strong>Pertussis (whooping cough) is a bacterial infection caused by <em>Bordetella pertussis</em>.</strong><ul><li>Following an initial catarrhal stage, an irritating cough gradually becomes a paroxysmal cough, usually within 1–2 weeks. The paroxysms are often followed by the characteristic 'whoop'. In young infants, apnoea may occur after coughing spasms instead of the 'whoop'. Pertussis can also present as a persistent cough without the other typical symptoms in adults and older children.</li><li>Severe complications and deaths are most common in infants younger than 6 months of age. Possible complications include pneumonia, or cerebral hypoxia resulting in brain damage. </li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/whooping-cough/\">Whooping cough</a>.</li></ul></li><li><strong>Historical evidence has shown that the pertussis vaccine is effective.</strong> Following the introduction of vaccination programmes, the incidence of pertussis declined sharply, only to rise in the 1970s when coverage fell due to safety concerns, and fall again when high vaccination coverage was resumed.<ul><li>Prior to the introduction of pertussis vaccination in the 1950s, average annual notifications of pertussis in the UK exceeded 120,000 cases<strong>.</strong> Since 2009–2010, vaccine coverage has exceeded 95%. </li><li>Despite this, a national outbreak of pertussis was declared in April 2012 following an increase in incidence to levels higher than the previous two decades. As a result, in September 2012, an immunization programme for pregnant women was introduced to protect infants from birth until they are protected by the routine childhood immunization programme; this is expected to continue until 2019<strong>.</strong></li><li>There were 2506 notifications of pertussis in England and Wales in 2014, including 10 deaths [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2016b</a>]. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">HPA, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2016c</a>]</p><!-- end field 3e69fc4d-8c64-49d3-84bf-27d7178c371d --><!-- end item 53e879b1-f6fd-4eb1-9d6e-5938122aefd7 -->","subChapters":[]},{"id":"07fe4939-d98c-5182-a5d0-7917acf3e964","slug":"pneumococcal-disease","fullItemName":"Pneumococcal disease","depth":3,"htmlHeader":"<!-- begin field b4f934fe-2029-4e45-82e2-d78b885caa21 --><h3>Pneumococcal disease</h3><!-- end field b4f934fe-2029-4e45-82e2-d78b885caa21 -->","summary":null,"htmlStringContent":"<!-- begin item 7995f89f-9b5e-4d7e-9ad2-1572a2de26ce --><!-- begin field 03150673-7476-4ced-9b61-443eecc674d6 --><ul><li><strong>Pneumococcal disease is caused by infection with </strong><em><strong>Streptococcus pneumoniae</strong></em> (an encapsulated Gram-positive coccus). It can present as:<ul><li>Non-invasive infection — sinusitis, otitis media, or pneumonia.</li><li>Invasive infection — bacteraemia, bacteraemic pneumonia, or meningitis. This is a major cause of morbidity and mortality, especially in the very young, the elderly, and the immunocompromised.</li></ul></li><li>Ninety types of encapsulated <em>S. pneumoniae</em> have been characterized, and 8–10 of these strains account for about 80% of invasive pneumococcal disease in children, and about 70% of serious pneumococcal disease in adults.</li><li><strong>The pneumococcal conjugate vaccine (PCV) probably prevents about 50–70% of cases of pneumococcal bacteraemia</strong> in children who receive it. However, current evidence suggests that it is ineffective at preventing non-bacteraemic pneumonia, otitis media, or acute exacerbations of bronchitis.</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-pneumococcal/\">Immunizations - pneumococcal</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2014c</a>]</p><!-- end field 03150673-7476-4ced-9b61-443eecc674d6 --><!-- end item 7995f89f-9b5e-4d7e-9ad2-1572a2de26ce -->","subChapters":[]},{"id":"a43fefe7-241b-5d61-8805-74cdb41f9267","slug":"poliomyelitis","fullItemName":"Poliomyelitis","depth":3,"htmlHeader":"<!-- begin field 4bed7e6d-d03e-44c9-87b5-b78afcb9606e --><h3>Poliomyelitis</h3><!-- end field 4bed7e6d-d03e-44c9-87b5-b78afcb9606e -->","summary":null,"htmlStringContent":"<!-- begin item 33845baa-d394-414f-9b09-23204d57b3b9 --><!-- begin field 1294173a-29a0-4323-8bc0-f848d6ac85b7 --><ul><li><strong>Poliomyelitis is a viral infection (type 1, 2, or 3) that attacks the nervous system.</strong><ul><li>The infection is most often not clinically apparent but may present with a range of symptoms. Acute disease may present with fever, fatigue, headache, and vomiting, often with stiffness of the neck and back (with or without paralysis). </li></ul></li><li><strong>Historical evidence has shown the poliomyelitis vaccine to be effective.</strong> Today, the disease is on the verge of worldwide eradication, with only isolated cases still occurring in a few countries.<ul><li>With the introduction of a poliomyelitis vaccine in the UK in 1956, the number of cases decreased to very low levels. The last reported case of natural poliomyelitis infection acquired in the UK was in 1984. </li><li>The World Health Organization has included the UK among the countries that are likely to have eliminated indigenous poliomyelitis infection.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">WHO, 2016</a>]</p><!-- end field 1294173a-29a0-4323-8bc0-f848d6ac85b7 --><!-- end item 33845baa-d394-414f-9b09-23204d57b3b9 -->","subChapters":[]},{"id":"1d4f0815-5966-5354-b531-3b04a8b24974","slug":"rotavirus","fullItemName":"Rotavirus","depth":3,"htmlHeader":"<!-- begin field 9e57a0e3-6dbf-44dc-bede-6a768c73e312 --><h3>Rotavirus</h3><!-- end field 9e57a0e3-6dbf-44dc-bede-6a768c73e312 -->","summary":null,"htmlStringContent":"<!-- begin item c237ec17-165f-41ef-a3d4-b2afa35f55bb --><!-- begin field a6b1f23f-847c-492e-8656-c996ab85321b --><ul><li><strong>Rotavirus infection causes a highly contagious gastroenteritis</strong> that usually lasts from three to eight days. <ul><li>People with rotavirus usually present with mild fever, severe diarrhoea, vomiting, and stomach cramps. Rotavirus infection may lead to dehydration. Transmission is thought to be by the faecal-oral route.</li><li>In the UK, rotavirus infection occurs mostly from January to March.</li><li>Although people of any age can become infected with rotavirus, most infections occur in children between 1 month and 4 years of age.<ul><li>Most children will have at least one episode of rotavirus before the age of 5 years.</li><li>About 130,000 children visit their GP each year with rotavirus gastroenteritis and an estimated 12,700 are admitted to hospital.</li></ul></li><li>Deaths from rotavirus in the UK are rare; about three to four deaths each year are attributable to rotavirus.</li></ul></li><li><strong>Rotarix<sup>®</sup> (the rotavirus vaccine offered as part of the UK childhood immunization programme since 2013) is over 85% effective at protecting against severe rotavirus gastroenteritis in infants up to two years of age.</strong><ul><li>From 2000 to 2013, the number of faecal specimens testing positive for rotavirus in England and Wales fluctuated between 13,000 and nearly 17,000, with the highest numbers in children younger than 5 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013i</a>].</li><li>CKS found no UK data on the impact of the UK rotavirus immunization schedule. However, data from the US (where rotavirus vaccination was introduced in 2006) show a significant decrease in rotavirus activity after the introduction of the vaccine in terms of the length of the rotavirus season, the number of positive rotavirus tests recorded, and the number of hospitalizations with diarrhoea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">CDC, 2015</a>].</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2015f</a>]</p><!-- end field a6b1f23f-847c-492e-8656-c996ab85321b --><!-- end item c237ec17-165f-41ef-a3d4-b2afa35f55bb -->","subChapters":[]},{"id":"fbf395c1-441e-5ebb-ac0d-d9c92f4e199f","slug":"rubella","fullItemName":"Rubella","depth":3,"htmlHeader":"<!-- begin field 86066ffb-6804-406a-90b1-90ede470eea9 --><h3>Rubella</h3><!-- end field 86066ffb-6804-406a-90b1-90ede470eea9 -->","summary":null,"htmlStringContent":"<!-- begin item 6b59f717-c827-4ceb-aa89-205277c55452 --><!-- begin field 300007c4-dea6-428d-accb-7c96d598f4f0 --><ul><li><strong>Rubella (German measles) is a mild infectious disease caused by a togavirus.</strong><ul><li>Clinical features include a low-grade fever, malaise, nasal congestion and runny nose, and mild conjunctivitis. An erythematous rash, usually seen on the face and neck and behind the ears, is usually transitory.</li><li>Maternal infection in the first 8–10 weeks of pregnancy may have serious consequences: fetal damage occurs in up to 90% of infants, resulting in multiple defects including cataracts; deafness; cardiac abnormalities; microcephaly; intrauterine growth retardation; and inflammatory lesions of the brain, liver, lungs, and bone marrow.</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/rubella/\">Rubella</a>.</li></ul></li><li><strong>Since universal immunization against rubella with t</strong><strong>he measles, mumps, and rubella vaccine (MMR) was introduced in 1988 for children, the number of pregnant women becoming infected has fallen dramatically. </strong><ul><li>There have only been a few confirmed cases of rubella in pregnant women since the early 1990s. Of the thirteen reported cases of rubella in pregnancy between 2005 and 2009, there were six confirmed cases of congenital rubella infection — all but one of these had mothers born outside the UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">HPA, 2011</a>].</li><li>There were three confirmed cases of rubella infection in England and Wales in 2014 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2016a</a>]. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">HPA, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2016d</a>]</p><!-- end field 300007c4-dea6-428d-accb-7c96d598f4f0 --><!-- end item 6b59f717-c827-4ceb-aa89-205277c55452 -->","subChapters":[]},{"id":"c4b64216-1f65-5ce4-8c51-20267fb2f219","slug":"tetanus","fullItemName":"Tetanus","depth":3,"htmlHeader":"<!-- begin field d6b278f1-3be1-465d-ba96-75aa15f4b8ee --><h3>Tetanus</h3><!-- end field d6b278f1-3be1-465d-ba96-75aa15f4b8ee -->","summary":null,"htmlStringContent":"<!-- begin item 4bc5099b-24c4-4283-827c-c3c13f78bea1 --><!-- begin field cbceb737-9492-4b11-b54e-008461f4d5ee --><ul><li><strong>Tetanus is an acute infectious disease caused by tetanus toxin,</strong> which is released when infection occurs with the anaerobic, spore-forming bacillus <em>Clostridium tetani</em>.<ul><li>Characteristic symptoms are muscle rigidity superimposed with painful contractions of skeletal muscle. The muscle stiffness usually involves the jaw (lockjaw) and neck and then becomes generalized.</li><li>Tetanus spores are present in soil, and may be transmitted through a minor wound. Therefore tetanus can never be eradicated. </li></ul></li><li><strong>The best evidence for the efficacy of the tetanus vaccine is the decline in the prevalence of the disease since immunization was introduced.</strong> It is now a rare disease.<ul><li>The tetanus case-fatality rate in England and Wales between 1984 and 2000 was 29%. Notifications, deaths, and laboratory reports of tetanus during this time were mainly from people over 45 years of age who had not been immunized. </li><li>There were four notifications of tetanus and one death from the disease in England and Wales in 2014.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2013k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2015g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-childhood/references/\">PHE, 2015h</a>]</p><!-- end field cbceb737-9492-4b11-b54e-008461f4d5ee --><!-- end item 4bc5099b-24c4-4283-827c-c3c13f78bea1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}